newsfilter
← Earnings
Earnings Releases·

NeuroPace — Third Quarter 2026 Earnings Summary

NeuroPace reported third-quarter 2026 total revenue of $23.1 million, with RNS System revenue reaching $22.9 million, representing a 1.4% year-over-year growth. The company revised its full-year 2026 revenue guidance downward to a range of $91 million to $92 million, citing the need to improve commercial execution following isolated account-level issues. Despite a net loss of $3.3 million for the quarter, the company achieved a positive adjusted EBITDA of $0.4 million and increased its non-GAAP gross margin to 84.8%. Strategic advancements include an FDA submission for the NeuroPace Remote Care system and the initiation of the AURORA study to support indication expansion for adolescents.

Company
NEUROPACE INC
Sector
Healthcare
Industry
Medical Devices